{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:11:36Z","timestamp":1784326296403,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1124\/dmd.121.000665","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T22:20:22Z","timestamp":1640038822000},"page":"235-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate"],"prefix":"10.1016","volume":"50","author":[{"given":"Daigo","family":"Asano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syoya","family":"Hamaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamim","family":"Zahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Nishiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Kazui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotoshi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Ikeguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Shinozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Yahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Yoshinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000665_bib1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/tx8004086","article-title":"Predicting circulating human metabolites: how good are we?","volume":"22","author":"Anderson","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000665_bib2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1080\/00498254.2021.1963009","article-title":"Evaluation of species differences in the metabolism of the selective NaV1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase","volume":"51","author":"Asano","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000665_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/cts.12734","article-title":"Prediction of metabolite-to-parent drug exposure: derivation and application of a mechanistic static model","volume":"13","author":"Callegari","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.121.000665_bib4","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/ps.4935","article-title":"Predicting mammalian metabolism and toxicity of pesticides in silico","volume":"74","author":"Clark","year":"2018","journal-title":"Pest Manag Sci"},{"key":"10.1124\/dmd.121.000665_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/tx8004357","article-title":"Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites","volume":"22","author":"Dalvie","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000665_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1530-0277.1985.tb05747.x","article-title":"Analysis of human alcohol- and aldehyde-metabolizing isozymes by electrophoresis and isoelectric focusing","volume":"9","author":"Duley","year":"1985","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1124\/dmd.121.000665_bib7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3390\/molecules25081937","article-title":"Metabolic-hydroxy and carboxy functionalization of alkyl moieties in drug molecules: prediction of structure influence and pharmacologic activity","volume":"25","author":"El-Haj","year":"2020","journal-title":"Molecules"},{"key":"10.1124\/dmd.121.000665_bib8","first-page":"239","article-title":"Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles","volume":"14","author":"Emoto","year":"2013","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000665_bib9","series-title":"Guidance for industry: Safety Testing of Drug Metabolites","year":"2020"},{"key":"10.1124\/dmd.121.000665_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/0049825021000048782","article-title":"mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates","volume":"33","author":"Graham","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000665_bib11","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.4155\/fmc.09.101","article-title":"Issues in the safety testing of metabolites","volume":"1","author":"Gross","year":"2009","journal-title":"Future Med Chem"},{"key":"10.1124\/dmd.121.000665_bib12","series-title":"M3(R2) Guidance: Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals.","year":"2010"},{"key":"10.1124\/dmd.121.000665_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0167-4781(92)90113-E","article-title":"Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450","volume":"1171","author":"Komori","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.121.000665_bib14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2174\/138920009790711832","article-title":"Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms","volume":"10","author":"Lai","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000665_bib15","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1517\/17425255.2010.497487","article-title":"Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters","volume":"6","author":"Lutz","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.121.000665_bib16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.121.000665_bib17","doi-asserted-by":"crossref","first-page":"15379","DOI":"10.1021\/bi0489309","article-title":"Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants","volume":"43","author":"Melet","year":"2004","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.121.000665_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.115.068601","article-title":"Mechanistic modeling to predict midazolam metabolite exposure from in vitro data","volume":"44","author":"Nguyen","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000665_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1124\/dmd.117.078279","article-title":"Estimation of circulating drug metabolite exposure in human using in vitro data and physiologically based pharmacokinetic modeling: Example of a high metabolite\/parent drug ratio","volume":"46","author":"Obach","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000665_bib20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/00498254.2016.1208854","article-title":"Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model","volume":"47","author":"Parmentier","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000665_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/00498254.2017.1422156","article-title":"Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes\u2122 model","volume":"49","author":"Parmentier","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000665_bib22","first-page":"1428","article-title":"Resorption, excretion and metabolism after intravenous and oral administration of HB 419-14C in man","volume":"19","author":"Rupp","year":"1969","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/dmd.121.000665_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1273\/cbij.17.38","article-title":"Prediction of the site of CYP3A4 metabolism of tolterodine by molecular dynamics simulation from multiple initial structures of the CYP3A4\u2013tolterodine complex","volume":"17","author":"Sato","year":"2017","journal-title":"Chem-Bio Informatics J"},{"key":"10.1124\/dmd.121.000665_bib24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/dmd.117.079848","article-title":"A decade in the MIST: Learnings from investigations of drug metabolites in drug development under the \u201cMetabolites in Safety Testing\u201d regulatory guidance","volume":"46","author":"Schadt","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000665_bib25","doi-asserted-by":"crossref","first-page":"17227","DOI":"10.1074\/jbc.M802180200","article-title":"Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid","volume":"283","author":"Schoch","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000665_bib26","doi-asserted-by":"crossref","first-page":"9497","DOI":"10.1074\/jbc.M312516200","article-title":"Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site","volume":"279","author":"Schoch","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000665_bib27","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1124\/dmd.114.060087","article-title":"Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator","volume":"42","author":"Sharma","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000665_bib28","doi-asserted-by":"crossref","first-page":"10204","DOI":"10.1021\/acs.jmedchem.0c00259","article-title":"Discovery of DS-1971a, a potent, selective NaV1.7 inhibitor","volume":"63","author":"Shinozuka","year":"2020","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.121.000665_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3769\/radioisotopes.24.3_167","article-title":"The biological fate of glipizide (II). The metabolism of glipizide in animals","volume":"24","author":"Sugihara","year":"1975","journal-title":"Radioisotopes"},{"key":"10.1124\/dmd.121.000665_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.120.000220","article-title":"Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor modulator","volume":"49","author":"Surapaneni","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000665_bib31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1124\/dmd.120.090928","article-title":"Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models","volume":"48","author":"Yamada","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000665_bib32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3109\/00498254.2012.656732","article-title":"Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes","volume":"42","author":"Yoda","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000665_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bmc.2011.12.004","article-title":"Prediction of sites of metabolism in a substrate molecule, instanced by carbamazepine oxidation by CYP3A4","volume":"20","author":"Yuki","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/dmd.121.000665_bib34","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.bcp.2009.08.003","article-title":"Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide","volume":"78","author":"Zharikova","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000665_bib35","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.bcp.2007.03.005","article-title":"Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon","volume":"73","author":"Zharikova","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000665_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1124\/dmd.117.078899","article-title":"Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development","volume":"46","author":"Zheng","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000665_bib37","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1124\/dmd.110.033555","article-title":"In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase","volume":"38","author":"Zientek","year":"2010","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624007487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624007487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:52:02Z","timestamp":1739955122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624007487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0090955624007487"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000665","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}